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Numerous molecular markers have been investigated by means of
univariate or multivariate analyses aimed at predicting breast
cancer patient outcome (Gasparini et al, 1993). So far, the majority
of such multivariate studies have been conducted in node-negative
patients in order to identify subgroups of patients which could
benefit from adjuvant treatment. In contrast, most node-positive
breast cancer patients systematically received adjuvant
chemotherapy. In support of this strategy, a recent meta-analysis
performed on 30 000 early breast cancer patients demonstrated
that adjuvant polychemotherapy (versus no chemotherapy) signifi-
cantly improved disease-free and overall survival; moreover,
it was suggested that anthracycline-containing regimens were
associated with greater efficiency as compared to cyclo-
phosphamide–methotrexate–fluorouracil (Early Breast Cancer
Trialists’ Collaborative Group, 1998). Since chemotherapy is
known to impair quality of life, identification of prognostic
markers in node-positive patients should be undertaken to avoid
ineffective adjuvant therapy in intrinsically resistant tumours. It
has been widely demonstrated that breast cancer tumours that are
positive for oestrogen receptors (ER) benefit most from hormonal
treatment (Early Breast Cancer Trialists’ Collaborative Group,
1992). Among tumoural parameters potentially useful to predict
responsiveness to chemotherapy, one can single out factors intrin-
sically related to the drug’s mechanisms of action. Among the
latter is the expression of c-erb-B2, reported to be a marker of
responsiveness to high-dose adjuvant chemotherapy in node-posi-
tive breast cancer patients (Muss et al, 1994). Also, a low tumoural
concentration of the lysosomal protease cathepsin D has been
significantly related to longer survival in node-positive breast
cancer patients receiving adjuvant chemotherapy (Namer et al,
1991). It has been established that defects in apoptosis caused by
the inactivation of p53 tumour suppressor gene can produce treat-
ment-resistant tumours, suggesting that p53 status may be an
important determinant of tumour response to anticancer drugs
(Lowe et al, 1994). Among factors more closely related to the drug
mechanisms of action, the expression of MDR1 (Pastan and
Gottesman, 1987) and, more recently, MRP (Barrand et al, 1994)
are particularly relevant for predicting the sensitivity to anthracy-
clines, which are still held as reference drugs in breast cancer treat-
ment.
Our purpose was to develop an original reverse transcription
polymerase chain reaction (RT-PCR)–enzyme-linked immuno-
sorbent assay (ELISA) multiplex assay for the coupled analysis of
MDR1 and MRP. This assay was applied in 85 node-positive
breast tumours from patients receiving anthracycline-based adju-
vant therapy. A long-term prognostic analysis including p53,
MDR1, MRP and other more classical prognostic factors was
performed with a median follow-up of 7.8 years.
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Summary The long-term prognostic value of tumoural MDR1 and MRP, along with p53 and other classical parameters, was analysed on
85 node-positive breast cancer patients receiving anthracycline-based adjuvant therapy. All patients underwent tumour resection plus
irradiation and adjuvant chemotherapy (the majority receiving fluorouracil–epirubicin–cyclophosphamide). Median follow-up for the 54 alive
patients was 7.8 years. Mean age was 53.7 years (range 28–79) and 54 patients were post-menopausal. MDR1 and MRP expression were
quantified according to an original reverse transcription polymerase chain reaction multiplex assay with colourimetric enzyme-linked
immunosorbent assay detection (b2-microglobulin as control). P53 protein was analysed using an immunoluminometric assay (Sangtec).
MDR1 expression varied within an 11-fold range (mean 94, median 83), MRP within a 45-fold range (mean 315, median 242) and p53 protein
from the limit of detection (0.002 ng mg–1) up to 35.71 ng mg–1 (mean 1.18, median 0.13 ng mg–1). P53 protein was significantly higher in
oestrogen receptor (ER)-negative than in ER-positive tumours (P = 0.039). The higher the p53, the lower the MDR1 expression (P = 0.015,
r = –0.27). P53 was not linked to progesterone receptor (PR) status, S phase fraction, or MRP. Significantly greater MDR1 expression was
observed in grade I tumours (P = 0.029). No relationship was observed between MDR1 and MRP. Neither MDR1 nor MRP was linked to ER
or PR status. Unlike MDR1, MRP was correlated with the S phase: the greater the MRP, the lower the S phase (P = 0.006, r = –0.42).
Univariate Cox analyses revealed that MDR1, MRP, p53 and S phase had no significant influence on progression-free or specific survival.
A tendency suggested that the greater the p53, the shorter the progression-free survival (P = 0.076 as continuous and 0.069 as
dichotomous). © 2000 Cancer Research Campaign
Keywords: p53; MDR1; MRP; breast cancer; multiplex assay
171
British Journal of Cancer (2000) 82(1), 171–177
© 2000 Cancer Research Campaign
Article no. bjoc.1999.0896
Received 10 February 1999
Revised 4 June 1999
Accepted 2 July 1999
Correspondence to: G Milano. E-mail: gerard.milano@cal.nice.fnclcc.frMATERIALS AND METHODS
Patients
Node-positive breast cancer patients were selected from an
updated computerized database according to the following criteria:
patients classified as node-positive (one node involved or more);
patients having received anthracycline-based adjuvant therapy;
patients followed up at our institute; patients with sufficient
remaining tumour material to assay MDR, MRP and p53. This
retrospective study was thus conducted on 85 patients. A descrip-
tion of the population is given in Table 1. Mean age was 53.7 years
(range 28–79). Fifty-four patients out of 85 were post-menopausal.
The histological grade, scored according to previously published
classifications (Bloom and Richardson, 1957; Scarff and Torloni,
1968), was not performed on the nine patients with lobular or
colloid carcinoma. Determination of the S phase fraction (flow
cytometry) was available in 41 patients. Cytosolic ERs and
progesterone receptors (PRs) were assayed by an immunoassay
performed with the Abbott Kit (Romain et al, 1994). Thresholds
for positivity were 10 and 15 fmol mg–1 prot for ER and PR
respectively.
All selected patients had undergone complete tumour resection
with axillary lymph node dissection. The mean number of
involved nodes was 5.4 (median 4.0, range 1–35). All patients
received post-operative irradiation and adjuvant chemo-
therapy. The chemotherapy protocol was FEC (fluorouracil–
epirubicin–cyclophosphamide) in 67 patients; FAC (fluoro-
uracil–adriamycin–cyclophosphamide) in 12 patients; epirubicin
alone in five patients; and AECF (adriamycin–
vindesine–cyclophosphamide–fluorouracil) in one patient. In
addition, 37 patients received tamoxifen, four received luteinizing
hormone releasing hormone (LHRH) and two underwent castra-
tion. All patients were regularly followed up with clinical,
radiological and biological examinations every 6 months for the
first 5 years and yearly examinations thereafter.
MDR1-MRP analysis
RNA extraction and RT
MDR1 and MRP were assayed on a tumoural fragment stored in
liquid nitrogen. Total RNA was isolated using the RNA NOW kit
from Biogentex (Ozyme, Montigny-le-Bretonneux, France) based
on a method derived from Chomczynski and Sacchi (1987). RNA
quality was checked by agarose gel electrophoresis. Quantification
was performed by densitometric analysis at 260 nm. One micro-
gram of total RNA was preincubated for 5 min at 65°C in a 20 ml
final volume of 50 mM Tris–HCl (pH 8.3), 75 mM potassium
chloride (KCl), 3 mM magnesium chloride (MgCl2), 1 mM of each
deoxyribonucleotide triphosphate and 2 mM of random hexamers
(Roche Diagnostics, Meylan, France). Fifty units of Expand
Reverse Transcriptase (Roche Diagnostics) and 20 units of human
placenta ribonuclease inhibitor (Amersham Pharmacia Biotech,
les Ulis, France) were then added and the mixture was incubated
for 30 min at 42°C followed by 5 min at 94°C.
Primers
The oligonucleotides used for MDR1 amplification were: MDR1
sense-strand: CCC ATC ATT GCA ATA GCA GG (nt. 2596–
2615) and MDR1 antisense-strand: GTT CAA ACT TCT GCT
CCT GA (nt. 2733–2752), which yield a 167 bp product
(Noonan et al, 1990).
For MRP amplification, oligonucleotides were: MRP sense-
strand: GAC CTG GAC TTC GTT CTC A (nt. 4109–4127) and
MRP antisense-strand: ACG TCC AGA TTC CTT CAT CC
(nt. 4381–4400), which yield a 291 bp product (Abbaszadegan
et al, 1994; slighty modified).
Those used for amplification of the reference gene
(b2-microglobulin) were: b2 m3 sense-strand: ACC CCC ACT
GAA AAA GAT GA (nt. 308–327) and b2 m4 antisense-strand:
ATC TTC AAA CCT CCA TGA TG (nt. 402–421), which yield a
120 bp product (Noonan et al, 1990).
All primer pairs span an intron to distinguish the PCR products
generated from cDNA and genomic DNA.
Three specific capture probes, 5¢biotinylated and purified by
high performance liquid chromatography (HPLC; Eurobio, les
Ulis, France) and corresponding to each amplification product,
were used for ELISA detection: MDR1 capture probe: GAA AAT
GTT GTC TGG ACA AGC (nt. 2628–2648); MRP capture probe:
GGG CTT ATT TCG GAT CAA CG (nt. 4210–4229);
b2-microglobulin capture probe: GTG GGA TCG AGA CAT GTA
AG (nt. 379–398).
PCR conditions
Briefly, 250 ng RNA equivalent were subjected to PCR amplifica-
tion in a 100 ml final volume containing 10 mM Tris–HCl (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, 200 mM of each deoxyribonucleotide
triphosphate (dATP, dCTP, dGTP), 190 mM of dTTP, 10 mM of
dUTP labelled with digoxigenin, 2.5 units of Taq polymerase and
250 nM of each primers pair for MDR1, MRP and b2-micro-
globulin. The multiplex amplification consisted of an initial 5-min
incubation at 94°C followed by 22 amplification cycles (94°C for
30 s, 55°C for 30 s and 72°C for 30 s).
PCR ELISA
MDR1 and MRP amplifications were performed using the PCR-
ELISA digoxigenin (DIG) labelling and the PCR-ELISA DIG
detection kits (Roche Diagnostics, Meylan, France) as previously
described by us (Castillo et al, 1997). The principle of PCR ELISA
is presented in Figure 1. The DIG-labelling reaction of the PCR
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Table 1 Description of the population
Number of patients %
Node involvement
1–3 nodes 42 49.4
4–7 nodes 20 23.5
8–35 nodes 23 27.1
Tumour size
T1 14 17.1
T2 54 65.9
T3 12 14.6
T4 2 2.4
Histological grade
I 22 25.9
II 35 41.2
III 19 22.3
Not scored 9 10.6
Positive receptor status
ER 61 71.8
PR 56 65.9
aTumour size was unknown for three patients.products was carried out during co-amplification of MDR1, MRP
and b2-microglobulin for an optimal number of cycles, in the pres-
ence of digoxigenin-labelled dUTP. These labelled products were
analysed with the three specific biotinylated capture probes which
allowed immobilization of the hybrid to a streptavidin-coated
microplate surface. The bound hybrid was detected by an anti-
digoxigenin antibody–peroxidase conjugate. Peroxidase activity
was evaluated by addition of the colourimetric substrate ABTS
and the absorbance was read at 405 nm. Results were arbitrarily
expressed as 10 000–fold the absorbance ratio (MDR1 or MRP/b2-
microglobulin).
P53 analysis
The cytosolic p53 protein (wild-type and mutated forms) was
analysed on a tumoural cytosol stored in liquid nitrogen, using a
monoclonal two-site single incubation immunoluminometric
assay (LIA-mat, Sangtec, Sweden). The sensitivity limit was
0.002 ng mg–1 prot. Cytosolic proteins were determined by the
Bradford colourimetric technique (Biorad Laboratories GmbH,
Munich, Germany). The intra-assay (n = 5) and inter-assay (n = 5)
reproducibility were 7% and 9.5% respectively.
Statistics
Gaussian distribution was evaluated according to normal proba-
bility plot and Kolmogorov–Smirnov good-fit test. Since p53,
MDR1, MRP and S phase fraction did not fit a Gaussian distribu-
tion, relationships between tumoural parameters were analysed
using non-parametric tests. Duration of survival was calculated
from the date of surgery. For specific survival, the end point was
breast cancer-related death. For progression-free survival, the end
point was either recurrence or metastasis. Survival curves were
computed using the Kaplan–Meier method. Two patients were lost
to follow-up and were considered as censored observations. At
time of analysis, 31 patients had died. Median follow-up was 83
months for the whole population and 94 months for alive patients.
The influence of tumoural parameters on specific and progression-
free survival was analysed according to the Cox proportional
hazard regression, using logarithm 10-transformed data for S
phase fraction, p53, MDR1 and MRP. Statistics were drawn up on
SPSS software (Chicago, IL, USA).
RESULTS
Characteristics of the RT-PCR–ELISA multiplex assay
Densitometric analysis showed that the 120-bp b2-microglobulin
fragment was significantly expressed after 18 cycles of PCR and
reached a plateau at 24 cycles. The 167-bp corresponding to
MDR1 and the 291-bp corresponding to MRP products were unde-
tectable up to 20 cycles. From 20 to 24 cycles, the three genes were
amplified with comparable kinetics (yields of PCR products were
55.9% for MDR1, 56.7% for MRP and 51.7% for b2-micro-
globulin). Amplification was thus performed at 22 cycles.
This RT-PCR–ELISA assay markedly increased the sensitivity
compared to classical detection, since MDR1 and MRP products
were undetectable on ethidium bromide-stained agarose gels after
22 cycles of amplification. The intra-day reproducibility deter-
mined on the same cDNA sample (n = 8) was 3.9% for MDR1 and
7.4% for MRP. The inter-day reproducibility (same cDNA sample)
resulting from five independent experiments was 25.8% for
MDR1 and 30.6% for MRP. In each series of analyses, an internal
control is used which allows correction to be done. The internal
control is an aliquot from a cDNA preparation obtained from a
tumour specimen. The correction is done by comparing the result
given by the internal control with the mean of repeated determina-
tions on previous series.
Description of tumoural parameters
The description of S phase fraction, p53, MDR1 and MRP is given
in Table 2. Wide inter-patient variability was observed for all para-
meters: S phase varied within a 26-fold range, MDR1 expression
within an 11-fold range, MRP within a 45-fold range and p53
protein from the limit of detection (0.002 ng mg–1) up to
35.71 ng mg–1 (two samples out of 90 had p53 concentrations
below the limit of detection). ER and PR were positive in 71.8%
and 65.9% of patients respectively.
Relationships between tumoural factors are reported in Table 3.
P53 protein level was significantly different according to ER status
(median twofold higher in ER-negative as compared to ER-posi-
tive, P = 0.039). A weak but significant negative correlation was
observed with MDR1: the higher the p53, the lower the MDR1
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DIG labelling (PCR)
Hybridization with a
biotinylated capture probe
Immobilization of the
hybrid on a streptavidin-
coated microtitreplate
Incubation with an
anti-digoxigenin–peroxidase
conjugate
Incubation with the
colourimetric substrate
ABTS
colourimetric reaction
dXTPs+DIG-dUTP
Figure 1 Principles of PCR ELISAexpression (P = 0.015, r = –0.27). P53 was not linked to PR status,
S phase fraction, MRP, and no clear relationship was observed
according to the histological grade. MDR1-mRNA was signifi-
cantly different according to the histological grade, with greater
expression in grade I tumours (P = 0.029). MDR1 expression was
not linked to the S phase fraction. Importantly, no relationship was
observed between MDR1 and MRP expression. Neither MDR1
nor MRP was linked to ER or PR status. Unlike MDR1, MRP-
mRNA was not different according to the tumour histological
grade, and was significantly correlated with the S phase fraction:
the greater the MRP-mRNA, the lower the S phase fraction
(P = 0.006, r = –0.42).
Survival analyses
At time of analysis, 39 patients had relapsed (12 local recurrences,
24 metastases, three patients with both metastases and local
relapse). Progression-free survival is illustrated in Figure 2. The
probability of 5-year progression-free survival was 0.64 with a
median progression-free survival of 108 months. Analyses of
prognostic factors are shown in Table 4. S phase fraction, MDR1
expression and MRP expression had no significant influence on
progression-free survival. The above factors were also tested as
categorial variables based on the median value (0 if lower than
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Table 2 Description of tumoural parameters
S phase p53 MDR1-mRNA MRP-mRNA
(%) (ng mg–1) (normalized/b2-microglobulin) (normalized/b2-microglobulin)
n 41 84 85 85
Mean 8.62 1.18 94 315
Median 6.38 0.13 83 242
s.d. 6.79 4.31 54 294
1st–3rd quartile 3.02–14.12 0.06–0.28 60–114 75–429
Min–max 1.19–30.40 ND–35.71 28–315 32–1452
ND, not detectable (< 0.002 ng ml–1).
Table 3 Tumoural parameters and relationships between them according to non-parametric tests
Histological grade PR status ER status
S Phase
MRP MDR 1
I II III Pos. Neg. Pos. Neg. (%)
p53 (ng ml–1) Median Median Median Median Median Median Median Spearman Spearman Spearman
0.09 0.20 0.13 0.13 0.12 0.11 0.21 r = 0.13 r = –0.08 r = –0.27
KW P = 0.055 MW P = 0.91 MW P = 0.039 P = 0.43 P = 0.45 P = 0.015
MDR1 Median Median Median Median Median Median Median Spearman Spearman
99 71 83 85 75 76 83 r = –0.21 r = 0.19
KW P = 0.029 MW P = 0.67 MW P = 0.89 P = 0.20 P = 0.078
MRP Median Median Median Median Median Median Median Spearman
290 150 258 218 272 226 259 r = –0.42
KW P = 0.13 MW P = 0.66 MW P = 0.95 P = 0.006
S phase (%) Median Median Median Median Median Median Median
2.54 6.38 15.94 4.66 11.41 4.02 13.07
KW P = 0.010 MW P = 0.048 MW P = 0.002
ER status 100% 74.3% 26.3% Pos. 51 10
Pos. Pos. Pos. Neg. 5 19
c2 P < 0.001 c2 P < 0.001
PR status 95.5% 68.6% 26.3%
Pos. Pos. Pos.
c2 P < 0.001
Pos., positive; Neg., negative; KW, Kruskal–Wallis test; MW, Mann–Whitney test; Spearman, Spearman rank correlation.
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Figure 2 Plot of cumulative progression-free survival according to
Kaplan–Meier method. Survival was calculated from the date of surgery; end
point was local recurrence and/or metastasis. A total of 85 patients were
analysed (39 events observed). Vertical bars indicate the 46 censored
observationsmedian, 1 if greater). However, when so doing, variables remain
non-significant. A tendency suggested that the greater the p53
concentration, the shorter the progression-free survival (P = 0.076
as continuous and 0.069 as categorial variable, Table 4). The only
significant predictor of progression-free survival was the histolog-
ical grade (P = 0.048), with a relative risk of 2.43 (95% confidence
interval 1.00–5.87) for grade II–III, as compared to grade I. The
influence of clinical tumour size (T1 vs T2 vs T3–T4) was close to
significance (P = 0.060).
Specific survival was analysed by considering the 25 breast
cancer-related deaths (Figure 3). Probability of specific survival at
5 years was 0.81. Univariate Cox analyses revealed that S phase
fraction, p53 protein level, MDR1 expression and MRP expression
had no significant influence on specific survival (Table 4). As for
progression-free survival, when tested as categorial variables (0 if
lower than median, 1 if greater), these parameters remain non-
significant. Also, the number of involved nodes was not a signifi-
cant predictor of specific survival. The influence of histological
grade was at the limit of significance (P = 0.078, Table 4).
DISCUSSION
During the last decade, a plethora of clinical studies investigating
the prognostic value of new tumoral markers in breast cancer has
been published. Most of them focused on axillary node-negative
patients in order to identify subgroups of at-risk patients who
might benefit from adjuvant therapy (Gasparini et al, 1993). The
scope of the present study was somewhat different. It aimed to
determine whether tumoural factors considered to be relevant for
drug efficacy could be helpful in predicting long-term outcome
(7.8 years median follow-up) in node-positive breast cancer
patients receiving anthracycline-based adjuvant chemotherapy. We
thus developed and validated a RT-PCR–ELISA multiplex assay
allowing simultaneous quantification of MDR1 and MRP mRNA
since expression of MDR1 and MRP is known to be linked to
anthracycline resistance phenotype (Filipits et al, 1996). Tumoural
p53 was also investigated since p53 is involved in apoptosis
control (Lowe et al, 1993; Shimamura and Fischer, 1996). In addi-
tion, it has been demonstrated that tumours expressing p53 wild-
type gene contain a high proportion of apoptotic cells which
regress after adriamycin treatment, whereas p53-mutated tumours
contain few apoptotic cells and continue to grow (Lowe et al,
1994). To our knowledge, the present study is the first conducted
in node-positive breast cancer patients receiving anthracycline-
based adjuvant chemotherapy, with simultaneous measurement of
p53, MDR1 and MRP. In addition, classical prognostic factors like
histological grading, node involvement, S phase fraction, ER and
PR were analysed.
As regards tumour size, histological grade and ER and PR status
(Table 1), the present cohort of 85 patients is a representative
subgroup of node-positive breast cancer patients (Muss et al,
1994). Also, the distribution of S phase fraction closely fits with
data previously published (Muss et al, 1994).
In the present study, p53 mutations were indirectly estimated by
measuring cellular retention of the p53 protein (immunolumino-
metric assay) which is markedly increased in p53-mutated cells
(Raybaud-Diogene, 1996). Tumoural p53 exhibited tremendous
inter-patient variability, with concentrations ranging from the limit
of detection (< 0.002 ng ml–1) up to 35.71 ng ml–1 (median value at
0.13). P53 was significantly higher in ER-negative tumours as
compared to ER-positive tumours (Table 3). P53 was not related to
PR status, MRP, or to S phase fraction (Table 3). This latter result,
obtained from a small group of 41 patients, contrasts with data
from Allred (1993), Muss (1994), Iacopetta (1998) and Levesque
(1998), who all reported a significant positive relationship
between proliferation rate (S phase or Ki-67) and p53 expression
Multiplex assay in node-positive breast cancer 175
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Table 4 Univariate Cox analyses for progression-free and specific survival
Progression-free Specific
Co-variable n survival survival
P RRa P RRa
Histological grade 76 0.048 0.078
I (reference group) 22
II–III 54 2.43 2.63
Tumour size 82 0.060 0.15
T1 (reference group) 14
T2 54 5.67 7.35
T3-T4 14 4.44 6.46
Number of nodes involved 85 0.81 0.98
1–3 (reference group) 42
4–7 20 0.84 1.11
> 7 23 1.14 1.04
Age 85 0.39 0.99 0.17 0.97
ER status (0 : neg; 1 : pos) 85 0.91 0.96 0.85 0.92
PR status (0 : neg; 1 : pos) 85 0.92 1.03 0.64 0.82
S phase as logarithm 10 41 0.20 2.57 0.16 3.42
S phase as categorialb 41 0.15 2.24 0.13 2.88
p53 as logarithm 10 84 0.076 1.40 0.38 1.24
p53 as categorialb 84 0.069 1.84 0.66 1.20
MDR1 as logarithm 10 85 0.37 0.53 0.62 0.63
MDR1 as categorialb 85 0.29 0.71 0.25 0.62
MRP as logarithm 10 85 0.82 1.09 0.63 0.79
MRP as categorialb 85 0.66 1.16 0.72 1.16
Neg, negative; Pos, positiive. a For any co-variable, the relative risk (RR) is
equal to the risk of death of a patient presenting the value Xi divided by the
risk of death of a patient presenting the value Xi-1. For categorial variables,
RR represents the relative risk of death between the two classes of the
variable. When RR>1, the risk of death rises when the variable increases;
when RR<1, the risk of death decreases when the variable increases.
bVariables analysed as categorial were recoded as 0 when < median and
1 when > median.
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Figure 3 Plot of cumulative specific survival according to Kaplan–Meier
method. Survival was calculated from the date of surgery; end point was
breast cancer-related death. A total of 85 patients were analysed (25 events
observed). Vertical bars indicate the 60 censored observationsor mutation. From the present set of 84 patients, p53 taken as
continuous or dichotomous variable was not able to predict either
long-term progression-free survival or specific survival, even
though a tendency was observed suggesting that the greater the
p53 concentration, the shorter the progression-free survival
(P = 0.076 as continuous and 0.069 as dichotomous variable,
Table 4).
So far, the main study performed in node-positive breast cancer
patients receiving adjuvant chemotherapy is that of Muss (1994)
who performed immunohistochemistry on 394 tumours and
demonstrated a significant prognostic value of p53 accumulation
and of S phase fraction on overall survival (univariate analyses),
but not on disease-free survival. Silvestrini et al (1996) investi-
gated the role of p53 (immunohistochemistry) on 240 node-posi-
tive, ER-positive post-menopausal breast cancer patients receiving
post-operative radiation plus tamoxifen: p53 expression was a
significant indicator of relapse-free survival both in univariate and
multivariate analysis including the number of nodes involved and
labelling index. There is still a need for further evaluation of the
value of p53 expression or mutations for predicting radio- or
chemo-sensitivity in breast cancer patients.
Overexpression of MDR1 and MRP-related proteins has been
demonstrated to be a major cause of the multidrug resistance
phenomenon, which is characterized by an increased efflux of
structurally unrelated drugs including anthracyclines, vinca-alka-
loids, epipodophyllotoxins and taxanes (Lautier et al, 1996). In
contrast to the abundance of published MDR1 studies, MRP
expression has so far been poorly investigated in breast cancer
(Nooter et al, 1997; Beck et al, 1998). In the present study, an
original RT-PCR–ELISA multiplex assay allowing simultaneous
analysis of MDR1 and MRP was developed, validated and applied
on 85 tumour specimens. Inter-patient variability for MRP was
greater than that observed for MDR1 (45-fold and 11-fold range
respectively, Table 2). No significant relationship was demon-
strated between MDR1 and MRP expression (P = 0.078, Table 3).
This finding corroborates the work by Filipits (1996) on 134
tumours and that of Dexter (1998) on 74 tumour specimens, but
contrasts with the data of Beck (1998) who reported a significant
correlation on 62 primary breast cancers. Of clinical relevance are
the recent data of Dexter (1998) who used competitive RT-PCR to
measure MDR1 and MRP expression and demonstrated that
expression of MDR1 was extremely low as compared to MRP. In
line with our data, Dexter et al (1998) showed that MDR1 and
MRP expression were independent of ER and PR status. In our
study, MDR1 expression was significantly greater in histological
grade I tumours as compared to grade II–III (Table 3). Noteworthy,
a significant negative correlation was demonstrated between MRP
expression and S phase fraction (Table 3). This observation may
explain the fact that breast tumours with a high proliferation rate
exhibit higher response rates to preoperative chemotherapy than
tumours with a low proliferation rate (Remvikos et al, 1989). In
addition, we observed a weak but significant negative correlation
between MDR1 expression and p53 concentrations (Table 3).
However, based on the previously reported stimulation of MDR1
promotor gene by a mutant p53 protein (Chin, 1992), an inverse
result would have been expected.
Analysed both as a continuous or a dichotomous variable,
neither MDR1 nor MRP expression was related to progression-
free survival which is dependent on the efficiency of anthracy-
cline-based adjuvant therapy (Table 4). So far, the value of MDR1
and/or MRP expression in predicting treatment efficacy in breast
cancer patients has not been clearly established (Linn, 1995;
Nooter, 1997). The consensus recommendations recently
published for measuring MDR1/P-glycoprotein expression in clin-
ical studies (Beck et al, 1996) will probably help to clarify the role
of MDR1 expression in predicting treatment outcome in breast
cancer patients. Using the previously published classification
of Scarff (1968) and Bloom (1957), histological grading was
presently scored taking into account the degree of differentiation,
nuclear polymorphism and the mitotic index. In the present long-
term prognostic study, the only significant factor was the histolog-
ical grading, linked to progression-free survival (P = 0.048, Table
4); a tendency was observed towards specific survival (P = 0.078,
Table 4).
In conclusion, the present study provides a new tool for simulta-
neous measurement of MDR1 and MRP expression in tumour
specimens. Tannock (1998) recently pointed out the need to
individualize treatment in order to improve the effectiveness
of chemotherapy and thus survival for breast cancer patients
receiving adjuvant chemotherapy. We hope the present MDR1-
MRP assay may contribute to better evaluation of such a strategy.
REFERENCES
Abbaszadegan MR, Futscher BW, Klimecki WT, List A and Dalton WS (1994)
Analysis of multidrug resistance-associated protein (MRP) messenger RNA in
normal and malignant hematopoietic cells. Cancer Res 54: 4676–4679
Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne
CK and McGuire WL (1993) Association of p53 protein expression with tumor
cell proliferation rate and clinical outcome in node-negative breast cancer.
J Natl Cancer Inst 85: 200–206
Barrand MA, Heppell-Parton AC, Wright KA, Rabbits PH and Twentyman PR
(1994) A 190-kilodalton protein overexpressed in non-p-glycoprotein-
containing multidrug resistant cells and its relationship to the MRP gene. J Natl
Cancer Inst 86: 110–117
Beck WT, Grogan TM, Willman C and 28 others (1996) Methods to detect P-
glycoprotein-associated multidrug resistance in patients’ tumors: consensus
recommendations. Cancer Res 56: 3010–3020
Beck J, Bohnet B, Brügger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C,
Niethammer D and Gekeler V (1998) Multiple gene expression analysis reveals
distinct differences between G2 and G3 stage breast cancers and correlations of
PKCn with MDR1, MRP and LRP gene expression. Br J Cancer 77: 87–91
Bloom HJ and Richardson WW (1957) Histological grading and prognosis in breast
cancer. Br J Cancer 11: 359–377
Castillo L, Milano G, Santini J, Demard F and Pierrefite V (1997) Analysis of
retinoic acid receptor b expression in normal and malignant laryngeal mucosa
by a sensitive and routine applicable reverse transcription-polymerase chain
reaction enzyme-linked immunosorbent assay method. Clin Cancer Res 3:
2137–2142
Chin KV, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the
promotor of the human MDR1 gene by ras and p53. Science 255: 459–462
Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Annal Biochem 162:
156–159
Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC
and Goldstein LJ (1998) Quantitative reverse transcriptase-polymerase chain
reaction measured expression of MDR1 and MRP in primary breast carcinoma.
Clin Cancer Res 4: 1533–1542
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of
early breast cancer by hormonal, cytotoxic, or immune therapy: 133
randomised trials involving 31 000 recurrences and 24 000 deaths among
75 000 women. Lancet 339: 71–85
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for
early breast cancer: an overview of the randomized trials. Lancet 352
930–942
Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D and
Pirker R (1996) MRP and MDR1 gene expression in primary breast carcinoma.
Clin Cancer Res 2: 1231–1237
Gasparini G, Pozza F and Harris AL (1993) Evaluating the potential usefulness of
new prognostic and predictive indicators in node-negative breast cancer
patients. J Natl Cancer Inst 85: 1206–1219
176 JM Ferrero et al
British Journal of Cancer (2000) 82(1), 171–177 © 2000 Cancer Research CampaignIacopetta B, Grieu F, Powell B, Soong R, McCaul K and Seshadri R (1998) Analysis
of p53 gene mutation by polymerase chain reaction-single-strand conformation
polymorphism provides independent prognostic information in node-negative
breast cancer. Clin Cancer Res 4: 1597–1602
Lautier D, Canitrot Y, Deeley RG and Cole SPC (1996) Multidrug resistance
mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol
52: 967–977
Levesque MA, Yu H, Clark GM and Diamandis EP (1998) Enzyme-linked
immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor
in a large breast cancer cohort. J Clin Oncol 16: 2641–2650
Linn SC, Giaccone G, Van Diest PJ, Blokhuis WMD, Van der Valk P, Van Kalken
CK, Kuiper CM, Pinedo HM and Baak JPA (1995) Prognostic relevance of
P-glycoprotein expression in breast cancer. Annal Oncol 6: 679–685
Lowe SW, Ruley HE, Jacks T and Housman DE (1993) P53-dependent apoptosis
modulates the cytotoxicity of anticancer agents. Cell 74: 957–967
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman
DE and Jacks T (1994) P53 status and the efficacy of cancer therapy in vivo.
Science 266: 807–810
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman
DR, Wood WC, Barcos M and Henderson IC (1994) C-erb B-2 expression and
response to adjuvant therapy in women with node-positive early breast cancer.
N Engl J Med 330: 1260–1266
Namer M, Ramaioli A, Fontana X, Etienne MC, Hery M, Jourlait A, Milano G,
Frenay M, François E and Lapalus F (1991) Prognostic value of total cathepsin
D in breast tumors. A possible role in selection of chemoresistant patients.
Breast Cancer Res Treat 19: 85–93
Noonan KE, Beck C and Holzmayer TA (1990) Quantitative analysis of MDR1
(multidrug resistance) gene expression in human tumors by polymerase chain
reaction. Proc Natl Acad Sci USA 87: 7160–7164
Nooter K, Brutel de la Riviere G, Look MP, Van Wingerden KE, Henzen-Logmans
SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G and Foekens JA (1997) The
prognostic significance of expression of the multidrug resistance associated
protein (MRP) in primary breast cancer. Br J Cancer 76: 486–493
Pastan I and Gottesman MM (1987) Multiple-drug resistance in human cancer.
N Engl J Med 316: 1388–1393
Raybaud-Diogène H, Tétu B, Morency R, Fortin A and Monteil RA (1996) P53
overexpression in head and neck squamous cell carcinoma: review of the
literature. Oral Oncol, Eur J Cancer 32B: 143–149
Remvikos Y, Beuzedoc P, Zajdela A, Voillemot N, Magdelenat H and Pouillart P
(1989) Correlation of pretreatment proliferative activity of breast cancer with
the response to cytotoxic chemotherapy. J Natl Cancer Inst 81:
1383–1387
Romain S, Formento JL, Guirou O, Francoual M, Milano G and Martin PM (1994)
Determination of oestrogen receptors by enzyme immunoassay. Technical
differences between laboratories and their consequences. Eur J Cancer 30:
740–746
Scarff RW and Torloni H (1968) Histological typing of breast tumors. Geneva:
World Health Organization: 13–20
Shimamura A and Fisher DE (1996) P53 in life and death. Clin Cancer Res 2:
435–440
Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P and
Salvadori B (1996) P53 and bcl-2 expression correlates with clinical outcome
in a series of node-positive breast cancer patients. J Clin Oncol 14:
1604–1610
Tannock IF (1998) Conventional cancer therapy: promise broken or promise
delayed. Lancet 351 (suppl II): 9–16
Multiplex assay in node-positive breast cancer 177
British Journal of Cancer (2000) 82(1), 171–177 © 2000 Cancer Research Campaign